866-997-4948(US-Canada Toll Free)

Cancer Immunology and Oncolytic Virology: Technologies and Global Markets

Published By :

BCC Research

Published Date : May 2017

Category :

Pharmaceutical

No. of Pages : 164 Pages

The global cancer immunotherapy market should reach $96.5 billion by 2021 from $73.0 billion in 2016 at a compound annual growth rate (CAGR) of 5.7%, from 2016 to 2021.
The US region of the global cancer immunotherapy market is the largest market. The market is expected to grow from $38.8 billion in 2016 to $50.6 billion in 2021 at a CAGR of 5.4% for the period 2016-2021.
The Japan region of the global cancer immunotherapy market is expected to grow from $6.4 billion in 2016 to $10.1 billion in 2021 at a CAGR of 9.6% for the period 2016-2021.
Chapter 1 Introduction
Goals and Objectives
Reasons for Doing This Study
Intended Audience
Scope of The Study
Information Sources for the Technology Assessment
Forecasting Methodology
Geographic Breakdown
Analyst's Credentials
Related BCC Research Reports
Chapter 2 Summary and Highlights
Chapter 3 Overview
Past and Present of Cancer Immunology
What is Cancer?
Cancer as a Genetic Disorder
Treating Cancer
Surgery
Radiation Therapy
Pharmaceutical Therapy
Challenges in Treating Cancer
Cancer and the Immune System
Immunotherapy
Towards Combination Immunotherapy
Focusing on Cell-mediated Adaptive Immunity
Fine Tuning Versus Boosting Cancer Immunity
Early Versus Advanced Stage Cancer Immunotherapy
Personalized Treatment Paradigm
Clinically Significant Types of Cancers
Lung Cancer
Diagnosis
Treatment
Prognosis
Breast Cancer
Diagnosis
Treatment
Prognosis
Colorectal Cancer
Diagnosis
Treatment
Prognosis
Stomach Cancer
Diagnosis
Treatment
Prognosis
Head and Neck Cancer
Diagnosis
Treatment
Prognosis
Leukemia
Diagnosis
Treatment
Prognosis
Cervical Cancer
Diagnosis
Treatment
Prognosis
Prostate Cancer
Diagnosis
Treatment
Prognosis
Melanoma of the Skin
Diagnosis
Treatment
Prognosis
Ovarian Cancer
Diagnosis
Treatment
Prognosis
Future of Checkpoint Inhibitors, Cancer Vaccines, and Oncolytic Virology
Chapter 4 Overview of Cancer Immunotherapy
Immune System and Immunotherapy
Therapeutic Monoclonal Antibodies
Checkpoint Inhibitors
Biological Response Modifiers
Interleukin Products
Interferons
Colony-stimulating Factors
Vaccines
Vaccines to Protect Against Cancer
Therapeutic Cancer Vaccines
Sipuleucel-T (Provenge)
GSK3377794 (NY ESO-1 TCR)
Axalimogene Filolisbac (ADXS11-011)
Axicabtagene Ciloleucel (KTE-C19)
ICT-107
DCVax-L
DPX-Survivac
Other
VEGFR and PDGFR Inhibitors
EGFR and HER2/NEU Inhibitors
Immunomodulators
BCR-ABL Inhibitors
Proteasome Inhibitors
BTK Inhibitors
Expanded Information on Selected Product Candidates and Recent Regulatory Applications
Midostaurin
Lartruvo (Olaratumab)
Inotuzumab Ozagamicin
Sacituzumab Govitecan (IMMU-132)
Epacadostat
Chapter 5 Oncolytic Virology
Oncolytic Virotherapy
T-VEC (Talimogene Laherparepvec)
DNX-2401
PEXA-VEC (Pexastimogene Devacirepvec)
CAVATAK (CVA21)
Reolysin
Enadenotucirev (ColoAd1)
GL-ONC1
TELOMELYSIN (OBP-301)
HF10
WO-12
Chapter 6 Major Markets
Markets for Immunotherapy Products
Markets for Oncolytic Virology Products
Chapter 7 Company Profiles
ABBVIE INC.
ADAPTIMMUNE
ADURO BIOTECH
ADVANTAGENE
ADVAXIS IMMUNOTHERAPIES
AMGEN
ARGOS THERAPEUTICS
ARIAD PHARMACEUTICALS
AROG PHARMACEUTICALS
ASERTA PHARMACEUTICALS
ASTELLAS
ASTRAZENECA
AVAX TECHNOLOGIES
BAVARIAN NORDIC
BAYER HEALTHCARE
BIOVEX
BOEHRINGER INGELHEIM
BOSTON BIOMEDICAL
BRISTOL-MYERS SQUIBB
CELL MEDICA
CELLDEX THERAPEUTICS
CELGENE CORP.
CHUGAI
COLD GENESYS
DAIICHI SANKYO CO.
DENDREON
DNATRIX
EISAI
ELI LILLY
F HOFFMANN LA ROCHE AG
GENELUX
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
HANMI PHARMACEUTICAL
HEAT BIOLOGICS
IMMUNE DESIGN
IMMUNOCELLULAR THERAPEUTICS LTD.
IMMUNOMEDICS INC.
IMMUNOVACCINE INC.
IMMUNOVATIVE THERAPIES
INCYTE CIORP.
INOVIO PHARMACEUTICALS INC.
JANSSEN PHARMACEUTICALS
KADMON PHARMACEUTICALS CORP.
KITE PHARMACEUTICALS INC.
KYOWA HAKKO KIRIN CO. LTD.
LIGAND PHARMACEUTICALS INC.
LION BIOTECHNOLOGIES
LOKON PHARMACEUTICALS AB
MEDIMMUNE
MERCK & CO.
MERCK KGAA
MERCK SERONO
MEDIGENE AG
MIRATI THERAPEUTICS
MULTIVIR INC.
NEWLINK GENETICS
NORTHWEST BIOTHERAPEUTICS
NOVARTIS PHARMA SERVICES AG
ONCOLYS BIOPHARMA INC.
ONCOLYTICS BIOTECH INC.
ONCOMED PHARMACEUTICALS INC.
ONCOS THERAPEUTICS LTD.
ONO PHARMACEUTICAL CO.
OTSUKA PHARMACEUTICAL CO., LTD.
PFIZER INC.
PLEXXIKON INC.
PORTOLA PHARMACEUTICALS INC.
PROVECTUS BIOPHARMACUETICALS INC.
PSIOXUS THERAPEUTICS LTD.
SANOFI SA
SEATTLE GENETICS
SHANGHAI SUNWAY BIOTECH CO. LTD.
SHENZHEN SIBIONO GENTECH
SILLAJEN BIOTHERAPEUTICS INC.
SPECTRUM PHARMACEUTICALS
TAKARA BIO INC.
TAKEDA CO. LTD.
TAPIMMUNE INC.
TARGOVAX
TEVA PHARMACEUTICAL INDUSTRIES LTD.
TG THERAPEUTICS INC.
TRACON PHARMACEUTICALS INC.
TRANSGENE
VCN BIOSCIENCES
VENTIRX
VERASTEM INC.
VIRALYTICS LTD.
VIRTTU BIOLOGICS LTD
VYRIAD
WESTERN ONCOLYTICS LTD.

List of Table

Table 1 : Summary Table: Global Market for Cancer Immunotherapy, by Region, Through 2021
Table 2 : Stages of Lung Cancer
Table 3 : Approved Monoclonal Antibodies
Table 4 : Approved Antibody Drug Conjugates
Table 5 : Selected Therapeutic Monoclonal Antibodies in Clinical Trial
Table 6 : Approved Checkpoint Inhibitors
Table 7 : Selected Checkpoint Inhibitors in Clinical Trials
Table 8 : Selected Approved Interferon Alpha Analogues
Table 9 : Selected Approved Colony-Stimulating Factors
Table 10 : Selected Clinical-Stage Cancer Vaccines in Development
Table 11 : Selected Clinical-Stage Small-Molecule Immunotherapies in Development
Table 12 : Global Market for Immunotherapy Products, by Region, Through 2021
Table 13 : Global Market for Immunotherapy Products, by Treatment Category, Through 2021
Table 14 : U.S. Market for Immunotherapy Products, by Treatment Category, Through 2021
Table 15 : European Market for Immunotherapy Products, by Treatment Category, Through 2021
Table 16 : Japanese Market for Immunotherapy Products, by Treatment Category, Through 2021
Table 17 : Rest of the World Market for Immunotherapy Products, by Treatment Category, Through 2021
Table 18 : Global Market for Immunotherapy Products, by Cancer Indication, Through 2021
Table 19 : Global Market for Immunotherapy Products for Lung Cancer Treatment, by Region, Through 2021
Table 20 : Global Market for Immunotherapy Products for Breast Cancer Treatment, by Region, Through 2021
Table 21 : Global Market for Immunotherapy Products for Leukemia Treatment, by Region, Through 2021
Table 22 : Global Market for Immunotherapy for Myeloma Treatment, by Region, Through 2021
Table 23 : Global Market for Immunotherapy Products for Colorectal Cancer Treatment, by Region, Through 2021
Table 24 : Global Market for Immunotherapy Products for Lymphoma Treatment, by Region, Through 2021
Table 25 : Global Market for Immunotherapy Products for Melanoma Treatment, by Region, Through 2021
Table 26 : Global Market for Immunotherapy Products for Kidney Cancer Treatment, by Region, Through 2021
Table 27 : Global Market for Immunotherapy Products for Bladder Cancer Treatment, by Region, Through 2021
Table 28 : Global Market for Immunotherapy Products for Head and Neck Cancer Treatment, by Region, Through 2021
Table 29 : Global Market for Immunotherapy Products for Stomach Cancer Treatment, by Region, Through 2021
Table 30 : Global Market for Immunotherapy Products for Other Cancer Treatment, by Region, Through 2021
Table 31 : Global Market for Therapeutic Antibodies, by Region, Through 2021
Table 32 : Global Market for Checkpoint Inhibitors, by Region, Through 2021
Table 33 : Global Market for Interleukins, by Region, Through 2021
Table 34 : Global Market for Interferons, by Region, Through 2021
Table 35 : Global Market for Colony-Stimulating Factors, by Region, Through 2021
Table 36 : Global Market for Small Kinase Inhibitors, by Region, Through 2021
Table 37 : Global Market for Proteasome Inhibitors, by Region, Through 2021
Table 38 : Global Market for Immunomodulators, by Region, Through 2021
Table 39 : Global Market for Cancer Vaccines, by Region, Through 2021
Table 40 : Global Market for Lung Cancer Treatment, by Category, Through 2021
Table 41 : Global Market for Breast Cancer Treatment, by Category, Through 2021
Table 42 : Global Market for Leukemia Treatment, by Category, Through 2021
Table 43 : Global Market for Myeloma Treatment, by Category, Through 2021
Table 44 : Global Market for Colorectal Cancer Treatment, by Category, Through 2021
Table 45 : Global Market for Lymphoma Treatment, by Category, Through 2021
Table 46 : Global Market for Melanoma Treatment, by Category, Through 2021
Table 47 : Global Market for Kidney Cancer Treatment, by Category, Through 2021
Table 48 : Global Market for Bladder Cancer Treatment, by Category, Through 2021
Table 49 : Global Market for Head and Neck Cancer Treatment, by Category, Through 2021
Table 50 : Global Market for Stomach Cancer Treatment, by Category, Through 2021
Table 51 : Global Market for Treatment of Other Types of Cancer, by Category, Through 2021
Table 52 : Global Market for Oncolytic Virotherapy, Through 2021
Table 53 : Global Market for Oncolytic Virotherapy, by Region, Through 2021
Table 54 : Global Market for Oncolytic Virotherapy, by Indication, Through 2021

List of Chart

Figure 1 : Summary Figure: Global Market for Cancer Immunotherapy, by Region, 2015-2021
Figure 2 : Annual Incidence and Mortality Data for Lung Cancer in the U.S., 1975-2015
Figure 3 : Annual Incidence and Mortality Data for Lung Cancer in Five E.U. Countries, 1975-2012
Figure 4 : Annual Incidence and Mortality Data for Lung Cancer in Japan, 1975-2015
Figure 5 : Annual Incidence and Mortality Data for Lung Cancer in the Rest of the World, 1975-2012
Figure 6 : Five-Year Survival Rates, by Lung Cancer Stage
Figure 7 : Five-Year Survival Rates for Lung Cancer in the U.S., 1975-2008
Figure 8 : Annual Incidence and Mortality Data for Breast Cancer in the U.S., 1975-2015
Figure 9 : Annual Incidence and Mortality Data for Breast Cancer in Five E.U. Countries., 1975-2012
Figure 10 : Annual Incidence and Mortality Data for Breast Cancer in Japan, 1975-2012
Figure 11 : Annual Incidence and Mortality Data for Breast Cancer in the Rest of the World, 1975-2012
Figure 12 : Five-Year Survival Rates, by Breast Cancer Stage
Figure 13 : Annual Incidence and Mortality Data for Colorectal Cancer in the U.S., 1975-2015
Figure 14 : Annual Incidence and Mortality Data for Colorectal Cancer in Five E.U. Countries, 1975-2012
Figure 15 : Annual Incidence and Mortality Data for Colorectal Cancer in Japan, 1975-2015
Figure 16 : Annual Incidence and Mortality Data for Colorectal Cancer in the Rest of the World, 1975-2012
Figure 17 : Five-Year Survival Rates, by Colorectal Cancer Stage
Figure 18 : Annual Incidence and Mortality Data for Stomach Cancer in the U.S., 1975-2012
Figure 19 : Annual Incidence and Mortality Data for Stomach Cancer in Five E.U. Countries, 1975-2012
Figure 20 : Annual Incidence and Mortality Data for Stomach Cancer in Japan, 1975-2015
Figure 21 : Annual Incidence and Mortality Data for Stomach Cancer in the Rest of the World, 1975-2012
Figure 22 : Five-Year Survival Rates, by Stomach Cancer Stage
Figure 23 : Annual Incidence and Mortality Data for Head and Neck Cancer in the U.S., 1975-2015
Figure 24 : Annual Incidence and Mortality Data for Head and Neck Cancer in Five E.U. Countries, 1975-2012
Figure 25 : Annual Incidence and Mortality Data for Head and Neck Cancer in Japan, 1975-2015
Figure 26 : Annual Incidence and Mortality Data for Head and Neck Cancer in the Rest of the World, 1975-2012
Figure 27 : Five-Year Survival Rates, by Head and Neck Cancer Stage
Figure 28 : Annual Incidence and Mortality Data for Leukemia in the U.S., 1975-2015
Figure 29 : Annual Incidence and Mortality Data for Leukemia in Five E.U. Countries, 1975-2012
Figure 30 : Annual Incidence and Mortality Data for Leukemia in Japan, 1975-2015
Figure 31 : Annual Incidence and Mortality Data for Leukemia in the Rest of the World, 1975-2012
Figure 32 : Annual Incidence and Mortality Data for Cervical Cancer in the U.S., 1975-2015
Figure 33 : Annual Incidence and Mortality Data for Cervical Cancer in Five E.U. Countries, 1975-2012
Figure 34 : Annual Incidence and Mortality Data for Cervical Cancer in Japan, 1975-2015
Figure 35 : Annual Incidence and Mortality Data for Cervical Cancer in the Rest of the World, 1975-2012
Figure 36 : Five-Year Survival Rates, by Cervical Cancer Stage
Figure 37 : Annual Incidence and Mortality Data for Prostate Cancer in the U.S., 1975-2015
Figure 38 : Annual Incidence and Mortality Data for Prostate Cancer in Five E.U. Countries, 1975-2012
Figure 39 : Annual Incidence and Mortality Data for Prostate Cancer in Japan, 1975-2015
Figure 40 : Annual Incidence and Mortality Data for Prostate Cancer in the Rest of the World, 1975-2012
Figure 41 : Five-Year Survival Rates, by Prostate Cancer Stage
Figure 42 : Annual Incidence and Mortality Data for Melanoma in the U.S., 1975-2015
Figure 43 : Annual Incidence and Mortality Data for Melanoma in Five E.U. Countries, 1975-2012
Figure 44 : Annual Incidence and Mortality Data for Melanoma in Japan, 1975-2015
Figure 45 : Annual Incidence and Mortality Data for Melanoma in the Rest of the World, 1975-2012
Figure 46 : Five-Year Survival Rates, by Melanoma Stage
Figure 47 : Annual Incidence and Mortality Data for Ovarian Cancer in the U.S., 1975-2015
Figure 48 : Annual Incidence and Mortality Data for Ovarian Cancer in Five E.U. Countries, 1975-2012
Figure 49 : Annual Incidence and Mortality Data for Ovarian Cancer in Japan, 1975-2015
Figure 50 : Annual Incidence and Mortality Data for Ovarian Cancer in the Rest of the World, 1975-2012
Figure 51 : Five-Year Survival Rates, by Ovarian Cancer Stage
Figure 52 : Market Share of Leaders in Cancer Immunotherapy, 2016
Figure 53 : Global Market Share of Leaders in Oncolytic Virotherapy, 2021

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *